Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179446 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 157
- Enrollment target
NCT06179446: Completed Phase 1 study, sponsored by Pfizer.
NCT06179446 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 157 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06179446, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 157 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. This study is seeking for participants who are: * between the ages of 18 to 49 years old or 65 to 84 years old. * willing and able to follow with all scheduled visits, treatment plan, laboratory tests, lifestyle changes, and other study procedures. * healthy as confirmed by medical history, physical examinations, and the study doctor. * capable of signing informed consent. Participants will receive either: * the pdmFlu vaccine, * a licensed influenza vaccine * a placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will not know which vaccine they receive. Participants will receive the study vaccines as a single shot in the arm. The study will compare participant experiences to help understand if the pdmFlu vaccine is safe and effective. Participants will take part in this study for up to 13 months. During this time, the participants will receive the study vaccine and take part in follow-up visits.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL pdmFlu vaccine
- BIOLOGICAL Licensed influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 1 |
What the finished NCT06179446 record still lists
NCT06179446 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06179446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06179446 about?
NCT06179446 is a clinical study titled "A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza". The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Infl...
What is the current status of trial NCT06179446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2023-12-13. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT06179446?
The interventions under investigation include: Placebo (BIOLOGICAL), pdmFlu vaccine (BIOLOGICAL), Licensed influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06179446?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06179446's enrollment target sits among peer trials
157 351st of 2000 higher than 1,650 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI